中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 7
Jul.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(7): 1710-1716

Metabolomic features of energy metabolic dysregulation and related targeted therapeutic strategies in acute-on-chronic liver failure

DOI: 10.12449/JCH260731
  • 1.

    Graduate School of Guangxi University of Chinese Medicine，Nanning 530222，China

  • 2.

    First Ward of Hepatology，The First Affiliated Hospital of Guangxi University of Chinese Medicine，Nanning 530023，China

Research funding:

Natural Seience Foundation of Guangxi Zhuang Autonomous Region (2023GXNSFAA026380)

More Information
  • Corresponding author: Wang Xiufeng， 52912236@qq.com （ORCID： 0000-0003-0841-5908）
  • Received Date: 2025-10-30
  • Accepted Date: 2025-12-09
  • Published Date: 2026-07-25
    Abstract
  • Acute-on-chronic liver failure is an acute decompensated syndrome that occurs on the basis of chronic liver disease and is characterized by a high short-term mortality rate. Metabolomics reveals the presence of significant energy metabolic reprogramming， manifesting as extensive dysregulation of glucose/lipid/amino acid metabolism， mitochondrial metabolism， and intestinal flora， and it closely interacts with systemic inflammation and immune imbalance， jointly promoting disease progression. The core metabolic phenotypes include suppressed gluconeogenesis， enhanced glycolysis， impaired β-oxidation， inhibited mitochondrial oxidative phosphorylation， ammonia metabolic imbalance， and gut microbiota dysbiosis. This article analyzes the latest studies on metabolomic and molecular mechanisms and systematically reviews the dysregulation characteristics of the five major metabolic networks. In terms of intervention for energy metabolism， this article summarizes the five strategies of glucose metabolism regulation， lipid metabolism intervention， mitochondria-targeted protection， gut microbiota rebalancing， and amino-acid optimization and assesses their application value and prospects for clinical translation， so as to provide a scientific basis for the treatment， alleviation， and even reversal of disease progression.

     

    • FullText(HTML)
  • loading
    • References(52)
  • [1]
    Choudhury A, Kulkarni A V, Arora V, et al. Acute-on-chronic liver failure(ACLF): The‘Kyoto consensus’-steps from Asia[J]. Hepatol Int, 2025, 19( 1): 1- 69. DOI: 10.1007/s12072-024-10773-4.
    [2]
    Liang J J, Wei X Y, Hou W X, et al. Liver metabolomics reveals potential mechanism of Jieduan-Niwan formula against acute-on-chronic liver failure(ACLF) by improving mitochondrial damage and TCA cycle[J]. Chin Med, 2023, 18( 1): 157. DOI: 10.1186/s13020-023-00858-x.
    [3]
    Zhang Y, Tan W T, Wang X B, et al. Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes[J]. J Hepatol, 2023, 79( 5): 1159- 1171. DOI: 10.1016/j.jhep.2023.07.011.
    [4]
    Liang X, Li P, Jiang J, et al. Transcriptomics unveils immune metabolic disruption and a novel biomarker of mortality in patients with HBV-related acute-on-chronic liver failure[J]. JHEP Rep, 2023, 5( 9): 100848. DOI: 10.1016/j.jhepr.2023.100848.
    [5]
    Clària J, Stauber R E, Coenraad M J, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64( 4): 1249- 1264. DOI: 10.1002/hep.28740.
    [6]
    Lee J M, Seo W Y, Song K H, et al. AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB.CRTC2 complex by orphan nuclear receptor small heterodimer partner[J]. J Biol Chem, 2010, 285( 42): 32182- 32191. DOI: 10.1074/jbc.M110.134890.
    [7]
    Kang Wenjuan, Wu Jing, Wu Jushan, et al. Effect and mechanism of silent information regulator 6 on gluconeogenesis in chronic-on-acute liver failure[J]. Chin J Hepatobiliary Surg, 2020, 26( 3): 165- 169. DOI: 10.3760/cma.j.issn.1007-8118.2020.03.002.

    康文娟, 吴静, 武聚山, 等. 沉默信息调节因子6对慢加急性肝衰竭糖异生的影响和机制探讨[J]. 中华肝胆外科杂志, 2020, 26( 3): 165- 169. DOI: 10.3760/cma.j.issn.1007-8118.2020.03.002.
    [8]
    Zhang J L, Hao L Y, Li S H, et al. mTOR/HIF-1α pathway-mediated glucose reprogramming and macrophage polarization by Sini decoction plus ginseng soup in ALF[J]. Phytomedicine, 2025, 137: 156374. DOI: 10.1016/j.phymed.2025.156374.
    [9]
    Li Yidong. The mechanism of PD-1 regulating glycolysis-mediated T lymphocyte dysfunction in acute-on-chronic liver failure[D]. Taiyuan: Shanxi Medical University, 2022. DOI: 10.27288/d.cnki.gsxyu.2022.001005.

    李奕东. PD-1调控糖酵解介导慢加急性肝衰竭T淋巴细胞功能障碍的机制研究[D]. 太原: 山西医科大学, 2022. DOI: 10.27288/d.cnki.gsxyu.2022.001005.
    [10]
    Ma Y J, Du L Y, Bai L, et al. Association between lactate-to-albumin ratio and short-term prognosis of acute-on-chronic liver failure treated with artificial liver support system[J]. Eur J Gastroenterol Hepatol, 2025, 37( 3): 327- 336. DOI: 10.1097/MEG.0000000000002885.
    [11]
    Morelli A M, Scholkmann F. Should the standard model of cellular energy metabolism be reconsidered Possible coupling between the pentose phosphate pathway, glycolysis and extra-mitochondrial oxidative phosphorylation[J]. Biochimie, 2024, 221: 99- 109. DOI: 10.1016/j.biochi.2024.01.018.
    [12]
    Liu G F, Wang X Z, Fan X L, et al. Metabolomics profiles in acute-on-chronic liver failure: Unveiling pathogenesis and predicting progression[J]. Front Pharmacol, 2022, 13: 953297. DOI: 10.3389/fphar.2022.953297.
    [13]
    Zhang I W, Curto A, López-vicario C, et al. Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure[J]. J Hepatol, 2022, 76( 1): 93- 106. DOI: 10.1016/j.jhep.2021.08.009.
    [14]
    Xie M, Yu Y, Kang R, et al. PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation[J]. Nat Commun, 2016, 7: 13280. DOI: 10.1038/ncomms13280.
    [15]
    Schlaepfer I R, Joshi M. CPT1A-mediated fat oxidation, mechanisms, and therapeutic potential[J]. Endocrinology, 2020, 161( 2): bqz046. DOI: 10.1210/endocr/bqz046.
    [16]
    Cai Q, Wang H, Zhu M Y, et al. Construction of a novel prognostic scoring model for HBV-ACLF liver failure based on dynamic data[J]. Sci Rep, 2024, 14( 1): 15198. DOI: 10.1038/s41598-024-63900-4.
    [17]
    Chen E Q, Wang M L, Zhang D M, et al. Plasma apolipoprotein A-V predicts long-term survival in chronic hepatitis B patients with acute-on-chronic liver failure[J]. Sci Rep, 2017, 7: 45576. DOI: 10.1038/srep45576.
    [18]
    Mo R D, Zhang Z L, Zhou Y M, et al. A new prognostic model based on serum apolipoprotein AI in patients with HBV-ACLF and acutely decompensated liver cirrhosis[J]. Lipids Health Dis, 2025, 24( 1): 35. DOI: 10.1186/s12944-025-02434-8.
    [19]
    Lu D S, Liu Y M, Luo Y H, et al. Intestinal farnesoid X receptor signaling controls hepatic fatty acid oxidation[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2022, 1867( 2): 159089. DOI: 10.1016/j.bbalip.2021.159089.
    [20]
    Zhang Y K, Fan Y C, Hu H L, et al. ZHX2 emerges as a negative regulator of mitochondrial oxidative phosphorylation during acute liver injury[J]. Nat Commun, 2023, 14( 1): 7527. DOI: 10.1038/s41467-023-43439-0.
    [21]
    Guo Jin, Shi Chunxia, Deng Wei, et al. Metabolic changes of macrophages in LPS-induced liver failure[J]. Chin Hepatol, 2022, 27( 9): 973- 977. DOI: 10.3969/j.issn.1008-1704.2022.09.008.

    郭金, 石春霞, 邓威, 等. 脂多糖诱导的肝衰竭中巨噬细胞能量代谢变化[J]. 肝脏, 2022, 27( 9): 973- 977. DOI: 10.3969/j.issn.1008-1704.2022.09.008.
    [22]
    Moreau R, Clària J, Aguilar F, et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF[J]. J Hepatol, 2020, 72( 4): 688- 701. DOI: 10.1016/j.jhep.2019.11.009.
    [23]
    Guan S T, Zhao L, Peng R Y. Mitochondrial respiratory chain super complexes: From structure to function[J]. Int J Mol Sci, 2022, 23( 22): 13880. DOI: 10.3390/ijms232213880.
    [24]
    Castaño-jiménez P A, Baltazar-díaz T A, González-hernández L A, et al. Deciphering the language of intestinal microbiota associated with sepsis, organ failure, and mortality in patients with alcohol-related acute-on-chronic liver failure(ACLF): A pioneer study in Latin America[J]. Microorganisms, 2025, 13( 5): 1138. DOI: 10.3390/microorganisms13051138.
    [25]
    Zhang Yongchao, Bi Yanzhen, Fang Xiao, et al. Protective effect of probiotics in rats with acute-on-chronic liver failure and related mechanism[J]. J Clin Hepatol, 2019, 35( 7): 1570- 1575. DOI: 10.3969/j.issn.1001-5256.2019.07.029.

    张永超, 毕研贞, 方萧, 等. 益生菌对慢加急性肝衰竭大鼠模型的保护作用及其机制[J]. 临床肝胆病杂志, 2019, 35( 7): 1570- 1575. DOI: 10.3969/j.issn.1001-5256.2019.07.029.
    [26]
    Meng Danli, Liang Liexin, Chen Jianhong, et al. Changes of intestinal short chain fatty acids in patients with hepatitis-B-related acute-on-chronic liver failure[J]. World Chin J Dig, 2019, 27( 6): 408- 414. DOI: 10.11569/wcjd.v27.i6.408.

    蒙丹丽, 梁列新, 陈建红, 等. 乙肝相关慢加急性肝衰竭患者肠道短链脂肪酸的变化研究[J]. 世界华人消化杂志, 2019, 27( 6): 408- 414. DOI: 10.11569/wcjd.v27.i6.408.
    [27]
    Sauerbruch T, Hennenberg M, Trebicka J, et al. Bile acids, liver cirrhosis, and extrahepatic vascular dysfunction[J]. Front Physiol, 2021, 12: 718783. DOI: 10.3389/fphys.2021.718783.
    [28]
    Clària J, Moreau R, Fenaille F, et al. Orchestration of tryptophan-kynurenine pathway, acute decompensation, and acute-on-chronic liver failure in cirrhosis[J]. Hepatology, 2019, 69( 4): 1686- 1701. DOI: 10.1002/hep.30363.
    [29]
    Zaccherini G, Aguilar F, Caraceni P, et al. Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF[J]. J Hepatol, 2021, 74( 5): 1117- 1131. DOI: 10.1016/j.jhep.2020.11.035.
    [30]
    Shalimar, Rout G, Kumar R, et al. Persistent or incident hyperammonemia is associated with poor outcomes in acute decompensation and acute-on-chronic liver failure[J]. JGH Open, 2020, 4( 5): 843- 850. DOI: 10.1002/jgh3.12314.
    [31]
    Kandalgaonkar M R, Kumar V, Vijay-kumar M. Digestive dynamics: Unveiling interplay between the gut microbiota and the liver in macronutrient metabolism and hepatic metabolic health[J]. Physiol Rep, 2024, 12( 12): e16114. DOI: 10.14814/phy2.16114.
    [32]
    Nanchal R, Subramanian R, Karvellas C J, et al. Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU: Cardiovascular, endocrine, hematologic, pulmonary, and renal considerations[J]. Crit Care Med, 2020, 48( 3): e173- e191. DOI: 10.1097/CCM.0000000000004192.
    [33]
    Zhang Y Q, Zhan L Q, Zhang L J, et al. Branched-chain amino acids in liver diseases: Complexity and controversy[J]. Nutrients, 2024, 16( 12): 1875. DOI: 10.3390/nu16121875.
    [34]
    Wu M C, Wu J, Liu K, et al. LONP1 ameliorates liver injury and improves gluconeogenesis dysfunction in acute-on-chronic liver failure[J]. Chin Med J, 2024, 137( 2): 190- 199. DOI: 10.1097/CM9.0000000000002969.
    [35]
    Yu Z J, Li J J, Ren Z G, et al. Switching from fatty acid oxidation to glycolysis improves the outcome of acute-on-chronic liver failure[J]. Adv Sci, 2020, 7( 7): 1902996. DOI: 10.1002/advs.201902996.
    [36]
    Wu W, Sun S S, Wang Y J, et al. Circulating neutrophil dysfunction in HBV-related acute-on-chronic liver failure[J]. Front Immunol, 2021, 12: 620365. DOI: 10.3389/fimmu.2021.620365.
    [37]
    Zhang Yu, Tian Xiaoling, Fu Qin, et al. Mechanism of Paeoniae Radix Rubra and Aconiti Lateralis Radix Praeparata regulating HIF-1α mediated glycolysis in treatment of immune damage in acute-on-chronic liver failure based on“application of both warming and clearing therapies”[J]. Shanghai J Tradit Chin Med, 2025, 59( 3): 85- 93. DOI: 10.16305/j.1007-1334.2025.2311028.

    张彧, 田晓玲, 付琴, 等. 基于“清温并用” 理论赤芍-附子调控HIF-1α介导糖酵解干预慢加急性肝衰竭大鼠免疫损伤的作用机制[J]. 上海中医药杂志, 2025, 59( 3): 85- 93. DOI: 10.16305/j.1007-1334.2025.2311028.
    [38]
    WU Muchen, Meng Qinghua. Nutritional assessment and clinical management of patients with acute-on-chronic liver failure[J]. J Clin Hepatol, 2021, 37( 4): 770- 774. DOI: 10.3969/j.issn.1001-5256.2021.04.006.

    吴牧晨, 孟庆华. 慢加急性肝衰竭患者的营养评估及临床管理[J]. 临床肝胆病杂志, 2021, 37( 4): 770- 774. DOI: 10.3969/j.issn.1001-5256.2021.04.006.
    [39]
    Kulkarni A V, Anand L, Vyas A K, et al. Omega-3 fatty acid lipid emulsions are safe and effective in reducing endotoxemia and sepsis in acute-on-chronic liver failure: An open-label randomized controlled trial[J]. J Gastroenterol Hepatol, 2021, 36( 7): 1953- 1961. DOI: 10.1111/jgh.15400.
    [40]
    Wang J L, Liu Y, Ding H R, et al. Mesenchymal stem cell-secreted prostaglandin E(2) ameliorates acute liver failure via attenuation of cell death and regulation of macrophage polarization[J]. Stem Cell Res Ther, 2021, 12( 1): 15. DOI: 10.1186/s13287-020-02070-2.
    [41]
    Li L, Liu Y R, Gao S, et al. Inhibition of 5-lipoxygenase pathway attenuates acute liver failure by inhibiting macrophage activation[J]. J Immunol Res, 2014, 2014: 697560. DOI: 10.1155/2014/697560.
    [42]
    Xie F, Dong J L, Zhu Y K, et al. HIF1a inhibitor rescues acute-on-chronic liver failure[J]. Ann Hepatol, 2019, 18( 5): 757- 764. DOI: 10.1016/j.aohep.2019.03.007.
    [43]
    Rodríguez S, Raurell I, Torres-arauz M, et al. A nitric oxide-donating statin decreases portal pressure with a better toxicity profile than conventional statins in cirrhotic rats[J]. Sci Rep, 2017, 7: 40461. DOI: 10.1038/srep40461.
    [44]
    Fu Qin. Mechanism of“paeonia lactiflora-aconitum carmichaelii” in the treatment of acute-on-chronic liver failure based on TNF-α-mitochondrial function-oxidative stress[D]. Changsha: Hunan University of Chinese Medicine, 2024. DOI: 10.27138/d.cnki.ghuzc.2024.000424.

    付琴. 基于TNF-α-线粒体功能-氧化应激研究“赤芍-附片”治疗慢加急性肝衰竭的作用机制[D]. 长沙: 湖南中医药大学, 2024. DOI: 10.27138/d.cnki.ghuzc.2024.000424.
    [45]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2024 version)[J]. J Chin Hepatol, 2024, 40( 12): 2371- 2387. DOI: 10.12449/JCH241206.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 12): 2371- 2387. DOI: 10.12449/JCH241206.
    [46]
    Yu X, Jin Y, Zhou W X, et al. Rifaximin modulates the gut microbiota to prevent hepatic encephalopathy in liver cirrhosis without impacting the resistome[J]. Front Cell Infect Microbiol, 2022, 11: 761192. DOI: 10.3389/fcimb.2021.761192.
    [47]
    Li J X, Xie S H, Chen M L, et al. Panose prevents acute-on-chronic liver failure by reducing bacterial infection in mice[J]. J Clin Invest, 2025, 135( 14): e184653. DOI: 10.1172/JCI184653.
    [48]
    Skladany L, Kubanek N, Adamcova Selcanova S, et al. 3PM-guided innovation in treatments of severe alcohol-associated hepatitis utilizing fecal microbiota transplantation[J]. EPMA J, 2024, 15( 4): 677- 692. DOI: 10.1007/s13167-024-00381-5.
    [49]
    Mo Xiaoai, Jiang Kaiping, Ma Xiaojun, et al. Clinical study of Fangfeng Tongsheng Powder on intestinal microecology in patients with liver failure[J]. Shenzhen J Integr Tradit Chin West Med, 2022, 32( 12): 14- 17. DOI: 10.16458/j.cnki.1007-0893.2022.12.004.

    莫小艾, 蒋开平, 马晓军, 等. 防风通圣散对肝衰竭患者肠道微生态影响的临床研究[J]. 深圳中西医结合杂志, 2022, 32( 12): 14- 17. DOI: 10.16458/j.cnki.1007-0893.2022.12.004.
    [50]
    Hou Yixin, Zhang Qun, Jiang Yuyong, et al. Effects of Liangxue Jiedu decoction on intestinal flora in patients with hepatitis B virus-related acute-on-chronic liver failure: An analysis based on high-throughput sequencing[J]. J Clin Hepatol, 2022, 38( 6): 1280- 1287. DOI: 10.3969/j.issn.1001-5256.2022.06.013.

    侯艺鑫, 张群, 江宇泳, 等. 基于高通量测序分析凉血解毒方对HBV相关慢加急性肝衰竭患者肠道菌群的影响[J]. 临床肝胆病杂志, 2022, 38( 6): 1280- 1287. DOI: 10.3969/j.issn.1001-5256.2022.06.013.
    [51]
    Verzár Z, Kiss R, BáLint C P, et al. Nutritional management of liver failure in the intensive care unit[J]. Medicina, 2025, 61( 7): 1210. DOI: 10.3390/medicina61071210.
    [52]
    Mehtani R, Premkumar M, Garg S, et al. Intravenous BCAA infusion does not lead to a sustained recovery from overt HE in ACLF-an open label randomized clinical trial[J]. J Clin Exp Hepatol, 2023, 13( 6): 977- 988. DOI: 10.1016/j.jceh.2023.05.015.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (61) PDF downloads(22) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return